This study examined @WHO recommended National Action Plan post-implementation changes in antibiotic utilization among 38 countries.
Authors include @mina-t.bsky.social & CP3's Tate Miner, @CallawayKim4, & @Sudamonas
Presented @IDWeekmtg & pub in @OFIDJournal
academic.oup.com/ofid/article...
Authors include @mina-t.bsky.social & CP3's Tate Miner, @CallawayKim4, & @Sudamonas
Presented @IDWeekmtg & pub in @OFIDJournal
academic.oup.com/ofid/article...
February 5, 2025 at 2:35 PM
This study examined @WHO recommended National Action Plan post-implementation changes in antibiotic utilization among 38 countries.
Authors include @mina-t.bsky.social & CP3's Tate Miner, @CallawayKim4, & @Sudamonas
Presented @IDWeekmtg & pub in @OFIDJournal
academic.oup.com/ofid/article...
Authors include @mina-t.bsky.social & CP3's Tate Miner, @CallawayKim4, & @Sudamonas
Presented @IDWeekmtg & pub in @OFIDJournal
academic.oup.com/ofid/article...
Adherence to #PrEP is crucial for effectiveness. 🆕analysis identified 4 adherence patterns that can inform targeted interventions to lower new #HIV infections.
Read more @OFIDJournal
academic.oup.com/ofid/article...
With CP3's @jennyciganic
Read more @OFIDJournal
academic.oup.com/ofid/article...
With CP3's @jennyciganic
October 23, 2024 at 12:18 PM
Adherence to #PrEP is crucial for effectiveness. 🆕analysis identified 4 adherence patterns that can inform targeted interventions to lower new #HIV infections.
Read more @OFIDJournal
academic.oup.com/ofid/article...
With CP3's @jennyciganic
Read more @OFIDJournal
academic.oup.com/ofid/article...
With CP3's @jennyciganic
✨️Recent Systematic Review and Meta-Analysis #OFIDJournal
Investigating Non-Penicillin Therapeutic Strategies in Syphilis Treatment
Penicillin monotherapy did not outperform ceftriaxone, azithromycin, or doxycycline
#idsky #medsky
academic.oup.com/ofid/article...
Investigating Non-Penicillin Therapeutic Strategies in Syphilis Treatment
Penicillin monotherapy did not outperform ceftriaxone, azithromycin, or doxycycline
#idsky #medsky
academic.oup.com/ofid/article...
Syphilis Treatment: Systematic Review and Meta-Analysis Investigating Nonpenicillin Therapeutic Strategies
This review and meta-analysis compared nonneurological syphilis treatments. Results indicate alternative therapies like doxycycline, ceftriaxone, and azith
academic.oup.com
December 6, 2024 at 4:41 PM
✨️Recent Systematic Review and Meta-Analysis #OFIDJournal
Investigating Non-Penicillin Therapeutic Strategies in Syphilis Treatment
Penicillin monotherapy did not outperform ceftriaxone, azithromycin, or doxycycline
#idsky #medsky
academic.oup.com/ofid/article...
Investigating Non-Penicillin Therapeutic Strategies in Syphilis Treatment
Penicillin monotherapy did not outperform ceftriaxone, azithromycin, or doxycycline
#idsky #medsky
academic.oup.com/ofid/article...
Our @BrighamPharmacy team has been on a vancomycin publication kick recently! Out today in @OFIDJournal, we report on our vanc accumulation rates in patients with obesity. Hint: it happens A LOT. Where's the #saynotovanco crowd at?! @PharmerMeg 😂
November 21, 2024 at 2:40 PM
Our @BrighamPharmacy team has been on a vancomycin publication kick recently! Out today in @OFIDJournal, we report on our vanc accumulation rates in patients with obesity. Hint: it happens A LOT. Where's the #saynotovanco crowd at?! @PharmerMeg 😂
Our @BrighamPharmacy team has been on a vancomycin publication kick recently! Out today in @OFIDJournal, we report on our vanc accumulation rates in patients with obesity. Hint: it happens A LOT. Where's the #saynotovanco crowd at?! @PharmerMeg 😂
November 21, 2024 at 2:28 PM
Our @BrighamPharmacy team has been on a vancomycin publication kick recently! Out today in @OFIDJournal, we report on our vanc accumulation rates in patients with obesity. Hint: it happens A LOT. Where's the #saynotovanco crowd at?! @PharmerMeg 😂
Our new article on Fidaxomicin for 1st CDI episode in ICHs is now available on @OFIDJournal
11,204 pts with 1st CDI episode
2,362 ICHs
The Fidaxomicin group had lower CDI recurrence compared to vancomycin (aOR 0.44, 95%CI 0.21–0.96)
#TxID
academic.oup.com/ofid/article/d…
11,204 pts with 1st CDI episode
2,362 ICHs
The Fidaxomicin group had lower CDI recurrence compared to vancomycin (aOR 0.44, 95%CI 0.21–0.96)
#TxID
academic.oup.com/ofid/article/d…
December 18, 2025 at 4:28 PM
Our new article on Fidaxomicin for 1st CDI episode in ICHs is now available on @OFIDJournal
11,204 pts with 1st CDI episode
2,362 ICHs
The Fidaxomicin group had lower CDI recurrence compared to vancomycin (aOR 0.44, 95%CI 0.21–0.96)
#TxID
academic.oup.com/ofid/article/d…
11,204 pts with 1st CDI episode
2,362 ICHs
The Fidaxomicin group had lower CDI recurrence compared to vancomycin (aOR 0.44, 95%CI 0.21–0.96)
#TxID
academic.oup.com/ofid/article/d…
I agree. And others …
@CIDJournal
@CMIJournal
@OFIDJournal
@LancetInfDis
@CIDJournal
@CMIJournal
@OFIDJournal
@LancetInfDis
Can colleagues amplify this appeal to journals and journal editors to open accounts on Bluesky, please? @MicrobioSoc @TrendsMicrobiol @CellCellPress @JBacteriology @jbiolchem @Nature @ScienceMagazine @PNASNews @MolMicroEditors @NAR_Open @NatureMicrobiol @NatureComms @ASMicrobiology 🙏
🦠🧪🧫🧬
🦠🧪🧫🧬
November 10, 2024 at 3:03 PM
I agree. And others …
@CIDJournal
@CMIJournal
@OFIDJournal
@LancetInfDis
@CIDJournal
@CMIJournal
@OFIDJournal
@LancetInfDis